Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed director
Fibrocell Science, Inc. (FCSC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2017 8-K Investor presentation, Quarterly results
Docs: "Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA - August 9, 2017 - Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “During the second quarter of 2017, we achieved important milestones that continue to advance the development of our gene therapy candidates for the treatment of rare and devastating diseases of the skin and connective tissue with high unmet needs,” said John Maslowski, President and Ch...",
"Corporate Presentation"
06/21/2017 8-K Form 8-K - Current report
05/22/2017 8-K Form 8-K - Current report
07/12/2016 8-K Form 8-K - Current report
05/18/2016 8-K Form 8-K - Current report
01/08/2016 8-K Investor presentation
Docs: "Corporate Presentation"
07/21/2015 8-K Investor presentation
Docs: "Investor Contact:",
"Investor Contact:",
"Corporate Presentation",
"Corporate Presentation"
04/21/2015 8-K Investor presentation
Docs: "Bylaws Amendment to the Fourth Amended and Restated Bylaws, effective April 20, 2015",
"Corporate Presentation"
01/12/2015 8-K Investor presentation
Docs: "Investor Presentation"
09/24/2014 8-K Investor presentation
Docs: "“R&D Day” Presentation",
"Fibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis Bullosa"
03/12/2014 8-K Investor presentation
Docs: "Investor Presentation"
01/13/2014 8-K Investor presentation
Docs: "Second Amendment to Exclusive Channel Collaboration Agreement between the Company and Intrexon",
"Supplemental Stock Issuance Agreement between the Company and Intrexon",
"Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome",
"Investor Presentation"
09/10/2013 8-K Form 8-K - Current report
08/05/2013 8-K Investor presentation
Docs: "Investor Presentation"
05/07/2013 8-K Form 8-K - Current report
01/09/2013 8-K Investor presentation
Docs: "Investor Presentation"
10/18/2012 8-K Form 8-K - Current report
08/09/2012 8-K Investor presentation
Docs: "Investor Presentation dated August 2012"
04/07/2011 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy